Roth Capital Has Bullish Estimate for Clene FY2027 Earnings

Clene Inc. (NASDAQ:CLNN) – Roth Capital lifted their FY2027 earnings per share estimates for shares of Clene in a research report issued on Monday, March 24th. Roth Capital analyst J. Aschoff now forecasts that the company will earn $6.41 per share for the year, up from their prior estimate of $6.30. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s FY2028 earnings at $9.04 EPS and FY2029 earnings at $12.47 EPS.

Several other analysts have also weighed in on CLNN. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of Clene in a report on Monday. HC Wainwright reissued a “buy” rating and issued a $31.00 price objective on shares of Clene in a research note on Monday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $55.25.

Clene Stock Performance

CLNN opened at $3.46 on Wednesday. Clene has a twelve month low of $3.37 and a twelve month high of $9.20. The firm has a market cap of $28.81 million, a price-to-earnings ratio of -0.66 and a beta of 0.27. The firm’s 50-day simple moving average is $4.52 and its 200-day simple moving average is $4.89.

Clene (NASDAQ:CLNN) last announced its quarterly earnings results on Monday, March 24th. The company reported ($1.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.13 million. Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CLNN. Fullcircle Wealth LLC bought a new stake in shares of Clene during the fourth quarter worth $69,000. SBI Securities Co. Ltd. bought a new stake in Clene during the 4th quarter worth about $69,000. Renaissance Technologies LLC acquired a new position in Clene during the 4th quarter valued at about $96,000. Geode Capital Management LLC boosted its stake in shares of Clene by 52.9% in the 4th quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares during the last quarter. Finally, Parsons Capital Management Inc. RI acquired a new stake in shares of Clene during the 4th quarter worth approximately $194,000. 23.28% of the stock is currently owned by institutional investors.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.